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Abstract
Background—African Americans have a higher incidence of prostate cancer and experience
poorer outcomes compared to Caucasian Americans. Racial differences in care are well
documented. However, few studies have characterized patients based on their prostate cancer risk
category, which is required to differentiate appropriate from inappropriate guideline application.
Methods—The medical records of a population-based sample of 777 North Carolina men with
newly diagnosed prostate cancer were studied to assess the association among patient race, clinical
factors and National Comprehensive Cancer Network (NCCN) guideline-concordant prostate
cancer care.
Results—African Americans presented with significantly higher Gleason scores (p=0.025) and
prostate specific-antigen levels (p=0.008) than Caucasian Americans. However, when clinical T
stage was considered as well, difference in overall risk category only approached statistical
significance (p=0.055). Across risk categories, African Americans were less likely to have surgery
(58.1% vs. 68.0%, p=0.004) and more likely to have radiation (39.0% vs. 27.4%, p=0.001)
compared to Caucasian Americans. However, 83.5% of men received guideline-concordant care
within one year of diagnosis, which did not differ by race in multivariable analysis (OR 0.83; 95%
CI 0.54–1.25). Greater patient-perceived access to care was associated with greater odds of
receiving guideline-concordant care (OR 1.06; 95% CI 1.01–1.12).
Conclusions—After controlling for NCCN risk category, there were no racial differences in
receipt of guideline-concordant care. Efforts to improve prostate cancer treatment outcomes
should focus on improving access to the health care system.
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Introduction
African-American (AA) men have a higher incidence of prostate cancer and experience
poorer outcomes compared to Caucasian-American (CA) men.1–5 Racial differences in
treatment have been suspected to account for the differential mortality. In particular, AAs
with early stage prostate cancer receive less aggressive care, such as active surveillance or
androgen deprivation therapy (ADT) alone, rather than surgery or radiation therapy;2, 3 AAs
also are less likely than CAs to receive ADT for advanced disease.5–7 The National
Comprehensive Cancer Network (NCCN) developed guidelines for the initial treatment of
prostate cancer based on patient life expectancy and cancer aggressiveness (“risk
categories”).8–10 Risk stratification is required to differentiate appropriate from
inappropriate application of treatment options, but few studies have characterized patients
based on risk categories. Treatment is influenced by the health care delivery environment
and the patient’s willingness to receive, and ability to access and pay for, the care
recommended.11 For AAs with prostate cancer in particular, insurance coverage, previous
forgone care, trust in the healthcare system, marital status, and education level have been
associated with care received for prostate cancer.12–14
No study of prostate cancer treatment has assessed directly whether there are racial
differences in guideline concordance for initial treatment of prostate cancer care across all




Date were drawn from the North Carolina Health Care Access Project (HCaP-NC), a follow-
up study of 811 men who were part of the North Carolina-Louisiana Prostate Cancer Project
(PCaP) cohort, a population-based study of 2258 AA and CA men with newly diagnosed
prostate cancer.15 The NC component originally enrolled 1031 men from July 2004 to
October 2007 in 42 counties. AA men were oversampled and represented 49% of
participants. Treatment and comorbidity data were abstracted from medical records.
Demographic and patient-reported information was obtained from the baseline interview.
Measures
The outcome receipt of guideline-concordant care, was a binary measure derived from
medical record abstraction. A determination was made based upon initial treatment received
versus that recommended using the NCCN guidelines, which assign patients to one of six
mutually exclusive prostate cancer risk categories based on clinical stage, Gleason grade,
and prostate-specific antigen (PSA) level. The NCCN grades its guidelines based on the
rigor of evidence on which they are based.10 The prostate guidelines represent uniform
NCCN expert consensus based on lower level evidence, including clinical experience,
although some recommended treatment options are based on higher-level evidence. The
2004 guideline was applicable at the time of first possible diagnosis date (July 1, 2004) and
changes in the guideline through 2007 affected neither the risk categories nor the
concordance algorithm (Figure 1). Only patients who had evidence of active surveillance or
watchful waiting as a treatment plan were considered to have received “expectant
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management.” Patients who received no documented follow up were distinguished them
from those who were followed for changes in PSA or symptoms according to the
guideline.10 Treatment performed within six, 12 or 18 months of diagnosis was considered
for calculating the outcome. Unadjusted results used either all treatment or initial treatment
within the treatment window.
The primary independent variable, race, was assessed by participant self-report.
NCCN recommends care be tailored for each patient based on life expectancy.10
Comorbidity and patient age were controlled for using the Charlson Comorbidity Index
(CCI) as a proxy for life expectancy.16 The CCI was scored from medical record abstraction.
Weights were assigned to each condition and age category and summed into a single score.
All liver disease was considered chronic.
The six risk and treatment combinations (Figure 1) were collapsed into five levels due to
small sample sizes in the two highest risk categories (“metastatic” disease included both
nodal involvement and metastases).
Five measures were included to assess how access moderated the effects of race on receipt
of guideline-concordant care: Insurance status (yes vs. no), marital status (married vs. not),
education level (more than high school vs. high school or less), medical mistrust (measured
using a validated five-item scale),17, 18 and perceived access to care (measured using nine
items resulting in a single summed score with possible values ranging from nine to 45).
Statistical Analysis
Racial differences were examined using Chi-squared tests and Fisher’s Exact tests for
categorical variables, and t-tests for continuous variables. Maximum likelihood estimation
(MLE) modeled the likelihood of receipt of NCCN guideline-concordant care. Likelihood
ratio (LR) tests assessed inclusion of demographic characteristics and access variables.
Model fit was assessed by comparing Akaike Information Criteria (AIC) and Hosmer and
Lemeshow’s goodness-of-fit. Complete case analysis was used to address missing data.
Except for summarizing therapies received, all other descriptive and regression results
adjusted for both the population sampling weights and PCaP response rate. All AAs were
included in the cohort sampling frame, but only 44% of CAs were asked to participate.15
AA’s and CA’s observations were weighted by their respective response rates since
response rates for inclusion in the original cohort differed by race. Descriptive statistics
were expanded by these factors to represent the NC prostate cancer population. Sensitivity
analyses assessed the effects of considering all comorbid liver disease as chronic; the
appropriate treatment window length; and NCCN guideline considerations to move
intermediate and high risk patients with multiple adverse factors to the next higher risk
category. Standard errors were adjusted using robust variance estimators to account for the
sampling and response weights. All analyses were conducted using Stata/IC 11.2.19
Results
AAs were significantly more likely than CAs to be uninsured (15.2% vs. 2.5%), to have
completed no more than high school (54.0% vs. 25.7%), and to be younger (61.2 vs. 63.8
years) (all p<0.001) (Table 1). CCI was similar between AAs and CAs. AAs presented with
significantly higher Gleason scores (p=0.025) and PSA levels (p=0.008), but their risk
category only approached statistical difference from CA men when combined with the
clinical T stage (p=0.055).
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Across all risk categories and combining all treatments received (Table 2), AAs received
less surgery (58.1% vs. 68.0%, p=0.004), more radiation (39.0% vs. 27.4%, p<0.001), and
more ADT (25.9% vs. 18.9%, p=0.022) than CAs, but similar rates of expectant
management (5.9% vs. 9.0%, p=0.094) and brachytherapy (8.6% vs. 6.9%, p=0.403). When
stratified by prostate cancer risk category, unadjusted treatment patterns were different by
race only among men with intermediate risk (p=0.017). More AAs received ADT plus
radiation than did CAs, which in this risk category is non-guideline-concordant. AAs also
were more likely to receive radiation and less likely to receive both surgery and expectant
management compared to CAs (Table 2).
The use of non-guideline concordant primary ADT was low (≤ 3.2%) across all risk
categories of clinically localized disease. The proportion of men who received no therapy
was low across all disease classifications. Expectant management was the least used
guideline concordant therapy for men with low and intermediate risk disease, the only
categories for which it is recommended, with 11.3% and 6.7% receiving it, respectively.
Population-adjusted rates showed that 83.5% of men received guideline-concordant care
within one year of diagnosis, which did not differ by patient race (Table 3). Guideline
concordance was relatively high in all categories, except for metastatic disease. Receipt of
guideline-concordant initial treatment differed by race only among men with intermediate
risk disease (concordance 75.3% AA vs. 85.9% CA, p=0.009).
Model 2, which excluded trust, marital status and education level, demonstrated the best
model fit among three models tested, though findings were generally consistent among all
models (Table 4). In multivariable analysis, receipt of guideline-concordant care did not
differ by race (OR 0.83; 95% CI 0.54–1.25), but patients with metastatic cancer had lower
odds of receiving guideline-concordant care (OR 0.09; 95% CI 0.03–0.31). Metastatic
patients had 91% lower odds of receiving guideline-concordant care than low-risk, clinically
localized patients. In addition, patient-perceived access to care was associated with greater
odds of receiving guideline-concordant care (OR 1.06; 95% CI 1.01–1.12); however,
insurance status was not (OR 0.82; 95% CI 0.36, 1.62). Sensitivity analyses varying the
classification of liver disease and varying the treatment window from six to 18 months did
not affect results.
Discussion
In a North Carolina population-based cohort of men with incident prostate cancer diagnosed
between 2004 and 2007, AA race was not associated with receipt, or lack of receipt, of
guideline-concordant care. These findings appear to contradict several studies demonstrating
that AAs experience different patterns of prostate cancer care than CAs;3, 5, 20 however,
these studies looked at broad patterns of care without consideration of risk status or
guideline recommendations. When patients were stratified by risk categories, racial
differences in care were found to be differences among appropriate treatment options for
most risk categories.
Patients received relatively high levels of guideline concordant care, which should be
reassuring for prostate cancer patients in NC. Another study that examined treatment
assigned based on D’Amico prostate cancer risk categories found similar proportions of
concordance for low- and intermediate risk patients (>80%), but lower proportions for high-
risk patients (60%) than were found in this study.21 No national benchmarks have been set
for prostate cancer care, but 80% adherence is a frequently used benchmark for care. Future
efforts to improve prostate cancer quality in NC should consider 80% adherence to be
achievable and consider establishing higher goals.
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In intermediate risk disease, although overall quality of care was relatively high, we found
racial differences in guideline concordance. Compared to CA men, more AA men in this
risk category received radiation therapy combined with ADT. Although evidence supporting
addition of ADT to radiation in intermediate risk cancer was emerging,22 it was not yet
recommended in 2004. Physicians treating these patients may have been innovators or early
adopters of this treatment advance, which was eventually incorporated into the 2010 NCCN
Guideline. However, the 2004 guidelines also allowed for moving patients with multiple
risks to the next higher risk category. In this case, higher risk would have made ADT
guideline-concordant. Reclassifying the 106 intermediate risk disease (and the 11 eligible
high risk disease patients) into the next higher category did not change overall results with
regard to race, CCI and perceived access to care. More intermediate-risk AA men received
therapy consistent with the higher risk category. We do not know whether physicians
treating these patients were innovators or reclassifying these patients based on multiple risk
factors; however, this raises the possibility that intermediate risk AAs may have actually
received better care than similar-risk CAs.
In men with nodal and metastatic disease, overall adherence was low. Only 32.3% of these
men appeared to receive appropriate care. Although few men were receiving ADT as their
initial treatment, it does not appear that physicians were delaying ADT until symptoms
arose, as has been suggested may be appropriate.23 Rather, overuse of aggressive care—
either surgery for those with nodal involvement only, or radiation for those with metastases
—led to most of the guideline discordance observed. However, the 2004 NCCN guidelines
suggest that surgery may be appropriate for those with T3 stage and nodal involvement,10
thus some of this care may be clinically appropriate. In addition, unlike clinical populations
of prevalent disease, we observed very few men with metastatic disease in this population-
based cohort of incident prostate cancer, thus estimates for this group may be unreliable.
While focusing on quality improvement in certain risk categories may be premature in light
of evolving evidence and guideline nuances, patients’ perceived access to care was
associated with receipt of guideline-concordant care. Overall, perceived access to care was
moderately high, but those who had the lowest levels of perceived access at baseline were
less likely to receive guideline-concordant care. Financial limitations (co-payments) and
physical access to care may both inhibit care. Lack of continuity in care or decreased levels
of comfort communicating with the healthcare provider also can represent diminished
access. Thus, improving these aspects of care delivery may be the most important quality
improvement targets in NC.
No association was found between having insurance and receiving guideline-concordant
care; however, the numbers of uninsured in this study were small and therefore, the analysis
of the contribution of insurance status lacked precision.
Guideline-concordant care in the high-risk NC cohort was estimated at 86.1% overall
compared to 60% in a study of SEER-Medicare21 and 50% among the CaPSURE cohort.24
CaPSURE is a continuously collected prostate cancer registry, initiated in 1996. Thus,
treatment patterns described from the registry represent the collective treatment provided
over more than a decade. During this time changes in reimbursement have occurred;25 new
technologies have emerged;26 and standards of care have changed.10, 27 Thus, comparison to
the 2004 guideline may not be appropriate, and comparisons of the CaPSURE cohort to our
2004–2007 cohort may not be valid. The differing age of the cohorts also may partially
explain the different findings among studies. The SEER-Medicare study is censored below
age 65, whereas HCaP-NC had no lower age limit (60% are less than 65 years old). In
CaPSURE, 46% of men are less than 65 years old.24 Nonetheless, when we restrict our
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cohort to those over 65 years of age, guideline-concordance for the high risk group falls only
slightly to 86% overall.
Unmeasured factors may be contributing to the differences found. Prostate cancer treatment
is highly provider-dependent.24, 28, 29 Our cohort may be seen by a limited number of
providers in a single state and may not reflect patterns of care present in other regions of the
country. Differences may reflect true differences in care in the populations studied. NC is
not represented among the SEER-Medicare registries and care delivery in NC may differ
markedly from those represented. For example, the distribution of AAs among healthcare
delivery systems may differ. The majority of the AA populations in the SEER sample are
concentrated in urban areas: Los Angeles, Detroit, Atlanta, San Francisco;30 whereas NC
AAs are more widely distributed outside of urban areas.31 Emerging evidence suggests
racial differences in healthcare may result from geographic differences.32
This study has a number of strengths. The study was designed to detect racial differences in
prostate cancer care. The quality of care was assessed using the well accepted NCCN
guidelines, which assign treatment by prostate cancer risk categories. Still, the study has
limitations. Whether the lack of implementation of guideline-concordant care results from
patient or provider preference was not addressed.9, 33, 34 The standard errors could be too
small because clustering by provider was not controlled for. However, since the main
hypothesis was not significant, the inability to control for clustering should not change the
results. Patients may have preferences for the aggressiveness of their care, independent of
clinical practice guidelines. However, patient level factors, which were included in the
analysis, did not explain the greater likelihood of discordant care provided in metastatic
disease. Finally, while NCCN guidelines are commonly used and represent the best level of
evidence available, the optimal treatment of clinically localized prostate cancer lacks a
strong evidence base. While we found care to be concordant with guidelines and distributed
equitably between racial groups, we do not know whether the guidelines themselves
represent the best care available. Moreover, the guidelines provide multiple treatment
options for localized disease. Some guideline-concordant treatments were not used as
frequently as others. Rates of expectant management were lower in this NC cohort than in
national cohorts,26 but this may be due to the much younger age of the NC prostate cancer
population.
Conclusion
NCCN guideline adherence was high in NC from 2004 to 2007 and did not differ by race.
Health policy makers and population scientists should not attribute racial differences in
prostate cancer outcomes to racial differences in treatment choices unless these differences
persist after adjustment for prostate cancer risk category.
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The 2004 to 2007 National Comprehensive Cancer Network guideline-concordant treatment
options are shown for each prostate cancer risk category.
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